Research statistics

Mazdutide research: publications and trials

What has been published on Mazdutide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Mazdutide works or is safe. For what it is and what the studies found, see the Mazdutide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

49

Since 2021

Publications in 2026 so far

23

Through November 15, 2026

Human clinical research

30.6%

15 of 49 classified

Registered clinical trials

46

ClinicalTrials.gov

Randomized controlled trials

12

Publications reporting an RCT in people

Systematic reviews and meta-analyses

14

Preclinical studies

10.2%

4 animal · 1 in vitro · 0 computational

Records that only mention it

11

Not counted above

Status in the library: In clinical trials. Groups: GLP-1 receptor agonists.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Mazdutide publications by year and evidence

2021, Human clinical research: 1 of 12022, Human clinical research: 2 of 22023, Human clinical research: 1 of 12024, Human clinical research: 1 of 82024, Reviews and meta-analyses: 7 of 82025, Human clinical research: 6 of 142025, Preclinical (animal, in vitro, computational): 2 of 142025, Reviews and meta-analyses: 4 of 142025, Other and not yet classified: 2 of 142026 (to date), Human clinical research: 4 of 232026 (to date), Preclinical (animal, in vitro, computational): 3 of 232026 (to date), Reviews and meta-analyses: 14 of 232026 (to date), Other and not yet classified: 2 of 23Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified0102030202120232026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
202110001
202220002
202310001
202410708
2025624214
2026 (to date)4314223

Study types

Randomized controlled trial12
Review11
Meta-analysis9
Systematic review5
Animal study4
Editorial, letter or other4
Case report2
Other clinical trial1
In vitro study1

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health38
Obesity and weight management34
Endocrinology20
Gastrointestinal5
Cardiovascular4
Cognitive health1
Immune system1
Musculoskeletal1
Neurological and mental health1

Registered clinical trials

9 of 17 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 19 · Not yet recruiting: 12 · Recruiting: 10 · Active, not recruiting: 4 · Unknown status: 1
Phase not applicable: 9 · Phase 1: 8 · Phase 1 / Phase 2: 4 · Phase 2: 9 · Phase 3: 11 · Phase 4: 5

TrialStatusPhaseStartedResults
Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 DiabetesNCT07924553 · 182 enrolledNot yet recruitingPhase not applicable2027-01—
Efficacy of Mazdutide on Fatty PancreasNCT07803705 · 194 enrolledNot yet recruitingPhase not applicable2026-11—
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNCT07775846 · 820 enrolledRecruitingPhase 42026-11—
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial CancerNCT07781150 · 128 enrolledNot yet recruitingPhase 22026-11—
Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese PatientsNCT07897305 · 700 enrolledNot yet recruitingPhase not applicable2026-10—
A Study of HRS-4729 Injection in Participants With Type 2 DiabetesNCT07843862 · 240 enrolledNot yet recruitingPhase 22026-10—
Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled TrialNCT07767552 · 249 enrolledNot yet recruitingPhase not applicable2026-09—
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNCT07713992 · 72 enrolledNot yet recruitingPhase not applicable2026-09—
Mazdutide for Weight Management and Gout in Adults With ObesityNCT07824895 · 30 enrolledNot yet recruitingPhase 42026-09—
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 · 116 enrolledRecruitingPhase 42026-09—
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 · 60 enrolledRecruitingPhase 42026-09—
Body-weight Reduction Effect on Portal Hypertension in Compensated CirrhosisNCT07797101 · 50 enrolledNot yet recruitingPhase not applicable2026-09—
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)NCT07654062 · 150 enrolledNot yet recruitingPhase 42026-07—
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementNCT07517042 · 420 enrolledRecruitingPhase not applicable2026-06—
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityNCT07633639 · 200 enrolledRecruitingPhase not applicable2026-05—
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityNCT07469800 · 336 enrolledRecruitingPhase 32026-04—
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorNCT07417306 · 912 enrolledNot yet recruitingPhase 32026-03—
A Study of IBI362 in Chinese Adolescents With Obesity or OverweightNCT07255209 · 180 enrolledRecruitingPhase 32025-12—
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNCT07135141 · 256 enrolledNot yet recruitingPhase not applicable2025-09—
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)NCT07083154 · 420 enrolledRecruitingPhase 32025-09—
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT06937749 · 181 enrolledActive, not recruitingPhase 22025-06—
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityNCT07000955 · 98 enrolledActive, not recruitingPhase 1, Phase 22025-06—
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2NCT06931028 · 260 enrolledRecruitingPhase 32025-06—
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)NCT06884293 · 479 enrolledActive, not recruitingPhase 32025-05—
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908 · 141 enrolledActive, not recruitingPhase 22025-03—
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderNCT06817356 · 308 enrolledCompletedPhase 22025-02—
Efficacy of Mazdutide for Treating PCOSNCT06519656 · 43 enrolledCompletedPhase 1, Phase 22024-10—
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesityNCT06536023 · 36 enrolledCompletedPhase 12024-08—
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityNCT06184568 · 349 enrolledCompletedPhase 32024-02—
A Study of IBI362 9 mg in Chinese Adults With ObesityNCT06164873 · 462 enrolledUnknown statusPhase 32023-12—
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06124807 · 179 enrolledCompletedPhase 22023-11Posted
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 · 1,481 enrolledRecruitingPhase 22023-11—
Pharmacokinetics of IBI362 in Subjects With and Without Renal ImpairmentNCT05793450 · 20 enrolledCompletedPhase 12023-05—
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsNCT05815680 · 48 enrolledCompletedPhase 12023-04—
A Study of IBI362 in Participants With Type 2 DiabetesNCT05606913 · 731 enrolledCompletedPhase 32023-01—
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseNCT05628311 · 319 enrolledCompletedPhase 32023-01—
A Study of LY3305677 in Participants With Obesity Or OverweightNCT05623839 · 32 enrolledCompletedPhase 12022-11—
A Study of IBI362 in Participants With Obesity or OverweightNCT05607680 · 610 enrolledCompletedPhase 32022-11—
A Study of IBI362 in Chinese Patients With Type 2 DiabetesNCT04965506 · 252 enrolledCompletedPhase 22021-09—
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsNCT04904913 · 328 enrolledCompletedPhase 22021-06—
Clinical Study of IBI362 in Healthy Chinese Male SubjectsNCT04773977 · 24 enrolledCompletedPhase 12021-03—
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMNCT04466904 · 42 enrolledCompletedPhase 1, Phase 22020-09—
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsNCT04440345 · 60 enrolledCompletedPhase 1, Phase 22020-06—
A Study of LY3305677 in Participants With Type 2 DiabetesNCT03928379 · 24 enrolledCompletedPhase 12019-10—
A Study of Multiple Doses of LY3305677 in Healthy ParticipantsNCT03325387 · 56 enrolledCompletedPhase 12017-10—
A Study of LY3305677 in Healthy ParticipantsNCT02972645 · 66 enrolledCompletedPhase 12016-12—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.

    Diabetes, obesity & metabolism · September 29, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42811393 · DOI 10.1111/dom.71400 · Reviews and meta-analyses

  2. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

    BMJ medicine · August 27, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42688617 · DOI 10.1136/bmjmed-2026-003026 · Reviews and meta-analyses

  3. Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

    Diabetology & metabolic syndrome · July 24, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42897592 · DOI 10.1186/s13098-026-02248-3 · Reviews and meta-analyses

  4. Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

    Diabetes, obesity & metabolism · July 6, 2026 · Meta-analysis · cited 1 times · open access

    PMID 42410325 · DOI 10.1111/dom.71058 · Reviews and meta-analyses

  5. Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.

    Diabetes, obesity & metabolism · March 10, 2026 · Meta-analysis · cited 3 times

    PMID 41804840 · DOI 10.1111/dom.70643 · Reviews and meta-analyses

  6. Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.

    Cardiology in review · February 19, 2026 · Meta-analysis · cited 1 times

    PMID 41711462 · DOI 10.1097/crd.0000000000001209 · Reviews and meta-analyses

  7. Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.

    American journal of therapeutics · September 1, 2024 · Meta-analysis · cited 3 times

    PMID 39292847 · DOI 10.1097/mjt.0000000000001756 · Reviews and meta-analyses

  8. Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.

    Endocrine · May 13, 2024 · Meta-analysis · cited 14 times

    PMID 38740695 · DOI 10.1007/s12020-024-03857-6 · Reviews and meta-analyses

  9. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.

    Frontiers in endocrinology · February 14, 2024 · Meta-analysis · cited 30 times · open access

    PMID 38440786 · DOI 10.3389/fendo.2024.1309118 · Reviews and meta-analyses

  10. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

    BMJ (Clinical research ed.) · July 8, 2026 · Systematic review · cited 8 times · open access

    PMID 42419792 · DOI 10.1136/bmj-2026-372161 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

    The New England journal of medicine · May 25, 2025 · Randomized controlled trial · cited 122 times

    PMID 40421736 · DOI 10.1056/nejmoa2411528 · Human clinical research

  2. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

    Nature communications · December 14, 2023 · Randomized controlled trial · cited 118 times · open access

    PMID 38092790 · DOI 10.1038/s41467-023-44067-4 · Human clinical research

  3. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

    Diabetes care · January 1, 2024 · Randomized controlled trial · cited 90 times · open access

    PMID 37943529 · DOI 10.2337/dc23-1287 · Human clinical research

  4. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

    EClinicalMedicine · October 7, 2022 · Randomized controlled trial · cited 83 times · open access

    PMID 36247927 · DOI 10.1016/j.eclinm.2022.101691 · Human clinical research

  5. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.

    EClinicalMedicine · August 13, 2021 · Randomized controlled trial · cited 63 times · open access

    PMID 34430840 · DOI 10.1016/j.eclinm.2021.101088 · Human clinical research

Latest publications

  1. Effectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report.

    Journal of clinical medicine · October 20, 2026 · Case report · cited 0 times · open access

    PMID 42941641 · DOI 10.3390/jcm15208128 · Human clinical research

  2. The GLP-1R/GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease.

    Diabetes, obesity & metabolism · October 14, 2026 · Animal study · cited 0 times · open access

    PMID 42875732 · DOI 10.1111/dom.71435 · Animal studies

  3. The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.

    Obesity reviews : an official journal of the International Association for the Study of Obesity · October 11, 2026 · Review · cited 0 times · open access

    PMID 42860310 · DOI 10.1111/obr.70228 · Reviews and meta-analyses

  4. Effects of Incretin-Based Pharmacotherapies on Lean Body Mass in Adults With Overweight, Obesity, or Type 2 Diabetes: A Systematic Review With Prespecified Network Meta-Analysis Feasibility Assessment.

    Cureus · October 10, 2026 · Review · cited 0 times · open access

    PMID 43005990 · DOI 10.7759/cureus.117738 · Reviews and meta-analyses

  5. Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.

    Diabetes, obesity & metabolism · September 29, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42811393 · DOI 10.1111/dom.71400 · Reviews and meta-analyses

  6. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

    BMJ medicine · August 27, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42688617 · DOI 10.1136/bmjmed-2026-003026 · Reviews and meta-analyses

  7. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

    The lancet. Diabetes & endocrinology · August 21, 2026 · Randomized controlled trial · cited 0 times

    PMID 42628555 · DOI 10.1016/s2213-8587(26)00160-9 · Human clinical research

  8. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.

    JAMA · August 4, 2026 · Editorial, letter or other · cited 0 times

    PMID 42251596 · DOI 10.1001/jama.2026.8427 · Commentary and other

  9. Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.

    JAMA · August 1, 2026 · Editorial, letter or other · cited 0 times

    PMID 42251768 · DOI 10.1001/jama.2026.10443 · Commentary and other

  10. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

    JAMA · August 1, 2026 · Randomized controlled trial · cited 8 times · open access

    PMID 42251595 · DOI 10.1001/jama.2026.8142 · Human clinical research

Browse all 49 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: IBI362; LY3305677; Mazdutide

((TITLE_ABS:"IBI362" OR CHEM:"IBI362" OR TITLE_ABS:"IBI 362" OR CHEM:"IBI 362") OR (TITLE_ABS:"LY3305677" OR CHEM:"LY3305677" OR TITLE_ABS:"LY 3305677" OR CHEM:"LY 3305677") OR (TITLE_ABS:"Mazdutide" OR CHEM:"Mazdutide")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Mazdutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/mazdutide